CLOVER HEALTH INVESTMENTS, CORP. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.68 USD | +1.49% |
|
+6.99% | -28.58% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,736 | 1,759 | 444.2 | 464.3 | 336.8 | - | - |
| Enterprise Value (EV) 1 | 1,664 | 1,479 | 340.5 | 341.4 | 254.3 | 265.1 | 244.7 |
| P/E ratio | -5.27 x | -2.62 x | -1.31 x | -2.15 x | -3.08 x | -3.43 x | -4.4 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 2.58 x | 1.19 x | 0.13 x | 0.23 x | 0.26 x | 0.25 x | 0.24 x |
| EV / Revenue | 2.47 x | 1 x | 0.1 x | 0.17 x | 0.2 x | 0.2 x | 0.17 x |
| EV / EBITDA | -22.4 x | -3.13 x | -1.14 x | -7.65 x | -51.2 x | 69.5 x | 15.8 x |
| EV / FCF | - | -5,224,509 x | -1,633,729 x | - | - | - | - |
| FCF Yield | - | -0% | -0% | - | - | - | - |
| Price to Book | - | 3.25 x | 1.28 x | - | - | - | - |
| Nbr of stocks (in thousands) | 103,500 | 472,802 | 477,944 | 487,644 | 495,292 | - | - |
| Reference price 2 | 16.77 | 3.720 | 0.9295 | 0.9521 | 0.6800 | 0.6800 | 0.6800 |
| Announcement Date | 3/1/21 | 2/23/22 | 2/28/23 | 3/12/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 672.9 | 1,472 | 3,477 | 2,034 | 1,275 | 1,336 | 1,404 |
| EBITDA 1 | -74.39 | -472 | -298.7 | -44.66 | -4.968 | 3.815 | 15.52 |
| EBIT 1 | -92.71 | -637 | -370.9 | -208.5 | -146.5 | -137.7 | -149.1 |
| Operating Margin | -13.78% | -43.27% | -10.67% | -10.25% | -11.49% | -10.31% | -10.62% |
| Earnings before Tax (EBT) 1 | -91.58 | -587.8 | -338.8 | -213.4 | -146.4 | -137.7 | -149.1 |
| Net income 1 | -136.4 | -587.8 | -338.8 | -213.4 | -114.9 | -103.9 | -86.17 |
| Net margin | -20.27% | -39.93% | -9.75% | -10.49% | -9.01% | -7.78% | -6.14% |
| EPS 2 | -3.180 | -1.420 | -0.7115 | -0.4425 | -0.2206 | -0.1984 | -0.1547 |
| Free Cash Flow | - | -283 | -208.4 | - | - | - | - |
| FCF margin | - | -19.23% | -5.99% | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Announcement Date | 3/1/21 | 2/23/22 | 2/28/23 | 3/12/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 427.2 | 432 | 874.4 | 846.7 | 856.8 | 898.8 | 527.8 | 513.6 | 482.1 | 510.3 | 321.2 | 321.1 | 314.4 | 318.4 | 323.5 |
| EBITDA 1 | -102.3 | -154.8 | -71.76 | -87.47 | -58.31 | -81.12 | -30.46 | 10.02 | -5.13 | -19.09 | -8.345 | 4.345 | 3.642 | -4.609 | - |
| EBIT 1 | -149.3 | -186.8 | -87.3 | -102.5 | -73.92 | -107.2 | -72.61 | -28.81 | -41.47 | -65.66 | -45.71 | -31.35 | -30.46 | -38.94 | - |
| Operating Margin | -34.94% | -43.23% | -9.98% | -12.11% | -8.63% | -11.92% | -13.76% | -5.61% | -8.6% | -12.87% | -14.23% | -9.76% | -9.69% | -12.23% | - |
| Earnings before Tax (EBT) 1 | -34.53 | -187.2 | -75.31 | -104.2 | -75.31 | -84.05 | -72.61 | -28.81 | -41.47 | -70.47 | -45.69 | -31.34 | -30.45 | -38.93 | - |
| Net income 1 | -34.53 | -187.2 | -75.31 | -104.2 | -75.31 | -84.05 | -72.61 | -28.81 | -41.47 | -70.47 | -37.59 | -23.12 | -22.4 | -31.78 | -29.1 |
| Net margin | -8.08% | -43.33% | -8.61% | -12.3% | -8.79% | -9.35% | -13.76% | -5.61% | -8.6% | -13.81% | -11.7% | -7.2% | -7.12% | -9.98% | -9% |
| EPS 2 | -0.0800 | -0.4400 | -0.1600 | -0.2188 | -0.1577 | -0.1759 | -0.1516 | -0.0601 | -0.0863 | -0.1463 | -0.0723 | -0.0436 | -0.0433 | -0.0614 | -0.0600 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/8/21 | 2/23/22 | 5/9/22 | 8/8/22 | 11/7/22 | 2/28/23 | 5/9/23 | 8/8/23 | 11/6/23 | 3/12/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | 71.5 | 280 | 104 | 123 | 82.5 | 71.7 | 92.1 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | -283 | -208 | - | - | - | - |
| ROE (net income / shareholders' equity) | - | -476% | -76.7% | -67.3% | -22% | -28.4% | -24.3% |
| ROA (Net income/ Total Assets) | -45.1% | -96.5% | - | - | - | - | - |
| Assets 1 | 302.1 | 609 | - | - | - | - | - |
| Book Value Per Share | - | 1.150 | 0.7300 | - | - | - | - |
| Cash Flow per Share | -2.760 | -0.6800 | -0.4300 | - | - | - | - |
| Capex | 0.69 | 0.72 | 4.47 | - | - | - | - |
| Capex / Sales | 0.1% | 0.05% | 0.13% | - | - | - | - |
| Announcement Date | 3/1/21 | 2/23/22 | 2/28/23 | 3/12/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
0.68
USD
Average target price
1.333
USD
Spread / Average Target
+96.08%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -28.58% | 337M | |
| +13.93% | 125B | |
| +18.37% | 101B | |
| -0.28% | 39.69B | |
| -33.18% | 36.86B | |
| -5.28% | 20.05B | |
| -13.82% | 3.08B | |
| -39.49% | 993M |
- Stock Market
- Equities
- CLOV Stock
- Financials Clover Health Investments, Corp.
